Antares Pharma Inc (NASDAQ:ATRS) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $3.84.

ATRS has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.50 price objective on shares of Antares Pharma in a research report on Wednesday, November 8th. Piper Jaffray Companies set a $3.00 price objective on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Monday, October 23rd. BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a research report on Friday, December 22nd. Finally, ValuEngine cut shares of Antares Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 16th.

Antares Pharma (NASDAQ ATRS) traded up $0.12 on Tuesday, reaching $2.08. 1,449,135 shares of the company traded hands, compared to its average volume of 1,001,635. Antares Pharma has a 1-year low of $1.58 and a 1-year high of $4.09. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89. The company has a market capitalization of $306.56, a PE ratio of -17.73 and a beta of 0.30.

Antares Pharma (NASDAQ:ATRS) last posted its quarterly earnings data on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). Antares Pharma had a negative net margin of 32.06% and a negative return on equity of 43.05%. The business had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.01 million. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. sell-side analysts anticipate that Antares Pharma will post -0.11 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of ATRS. Schwab Charles Investment Management Inc. lifted its holdings in shares of Antares Pharma by 84.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 533,576 shares of the specialty pharmaceutical company’s stock worth $1,719,000 after acquiring an additional 244,483 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Antares Pharma by 213.7% in the second quarter. Bank of New York Mellon Corp now owns 525,506 shares of the specialty pharmaceutical company’s stock worth $1,692,000 after acquiring an additional 357,991 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Antares Pharma in the second quarter worth about $120,000. JPMorgan Chase & Co. lifted its holdings in shares of Antares Pharma by 275.9% in the second quarter. JPMorgan Chase & Co. now owns 127,438 shares of the specialty pharmaceutical company’s stock worth $410,000 after acquiring an additional 93,538 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Antares Pharma by 35.6% in the second quarter. Wells Fargo & Company MN now owns 1,041,096 shares of the specialty pharmaceutical company’s stock worth $3,352,000 after acquiring an additional 273,496 shares during the last quarter. 34.88% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Antares Pharma Inc (ATRS) Receives $3.84 Consensus Price Target from Brokerages” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/02/09/antares-pharma-inc-atrs-receives-3-84-consensus-price-target-from-brokerages.html.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.